Abstract: The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.

Abstract: Compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection; pharmaceutical compositions comprising these compounds; and the use of these compounds and compositions in the prevention or treatment of such diseases.

Abstract: The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.

Abstract: Chemical compounds which are antagonists of Monocyte Chemoattractant Protein-1 (MCP-1) function, pharmaceutical compositions comprising these compounds, methods of treatment employing these compounds and compositions, and processes for preparing these compounds. The compounds are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Orohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection.

Abstract: A potentiator for interferon and an antiviral activity-potentiating composition containing interferon and its potentiator are provided. The potentiator is a mixture of flavin adenine dinucleotide (FAD) and porcine liver extract.

Abstract: A maillard reaction inhibitor comprising, as the principal component, an eight-structural polymer of 3-oxygermylpropionic acid represented by the following stereostructure (I): ##STR1## wherein R represents --CH.sub.2 CH.sub.2 COOH, and m is a weight average polymerization degree calculated on the basis of the weight average molecular weight of propagermanium propyl ester and is 137.+-.84 (137 on average with a standard deviation of .+-.3.sigma.); and having the following minimum constitutional unit:(O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOHand the following empirical formula:C.sub.6 H.sub.10 Ge.sub.2 O.sub.7,a method for inhibiting the Maillard reaction, and a method for preventing and treating diseases caused by Maillard reaction such as diabetes and concurrent diseases thereof.

Abstract: Wart of human being is prevented or cured by administration of a pharmaceutical composition containing an eight structural polymer of 2-oxygermylpropionic acid having an empirical formula of C.sub.6 H.sub.10 Ge.sub.2 O.sub.7, a minimum constitutional unit of (O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH and the following stereostructure: ##STR1## wherein R stands for --CH.sub.2 CH.sub.2 COOH and m is an integer of 137.+-.84.

Abstract: The invention provides a novel glycoside which contains as the aglycon a 4-(substituted phenyl)piperazine-1-yl derivative of glycyrrhetinic acid and 11-deoxo-glycyrrhetinic acid or their derivative as well as a composition for the treatment of virus infection, which contains these compounds as a main active component.

Abstract: A composition comprising an organogermanium compound represented by the formula ##STR1## wherein n is an integer of 1 or more, R is hydrogen, alkyl, --COOH, --COOR', phenyl, ##STR2## and R' is a lower alkyl and a high molecular carrier, as well as an immunity adjusting agent comprising the composition. The treatment of hepatitis with compositions containing this germanium derivative.

Abstract: A composition comprising an organogermanium compound represented by the formula ##STR1## wherein n is an integer of 1 or more, R is hydrogen, alkyl, --COOH, --COOR', phenyl, ##STR2## and R' is a lower alkyl and a high molecular carrier, as well as an immunity adjusting agent comprising the composition.

Abstract: A 3-oxygermylpropionic acid preparation is provided, which activates the action of 3-oxygermylpropionic acid having the general formula:[(O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH]n wherein n=an integer of at least 1 and is readily solubilized and disintegrated in vivo. The present preparation is manufactured by compression-molding at high pressure a composition comprising 3-oxygermylpropionic acid and two or more low-molecular substance of high solubility in water. The low-molecular substances are selected from the group consisting of white sugar, sorbitol, fructose, sucrose, glucose, lactose, mannitol and sodium chloride.

Abstract: An organic germanium compound to be effectively used for curing AIDS or making AIDS asymtomatic in various forms is expressed by the following rational formula: ##STR1## wherein n is an integer of 1 or 2 or more, is in the form of a white acicular or needle crystal, shows a solubility of 1.570/100 ml in water at 25.degree. C. and exhibits a melting (decomposition) point of 240.degree. C.

Abstract: A novel polymer-metal complex containing quaternary nitrogen atoms, which is obtained by subjecting polyethylenepolyamine or polyethyleneimine to a reaction with a bifunctional compound represented by the formulaY--A--Zwherein Y and Z are same or different and are --CH.sub.2 X, --CH(OH)CH.sub.2 X or ##STR1## group, respectively, A is a single bond, --(CH.sub.2).sub.m --, --CH.sub.2 --O--CH.sub.2 -- or --CH.sub.2 --O--(CH.sub.2).sub.k --O--CH.sub.2 -- group, X is chlorine, bromine or iodine atom, m is an integral of 1 to 3, and k is an integral of 1 to 4, and then subjecting the resulting cross-linked polymer to a coordination of a polyvalent metal ion, a salt thereof, a process for the preparation thereof and a pharmaceutical agent comprising the same.